• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

mRNA-1273 或 Omicron 加强针在接种疫苗的猕猴中引发相似的 B 细胞扩增、中和反应，并提供针对 Omicron 的保护。

mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits similar B cell expansion, neutralizing responses, and protection from Omicron.

机构信息

Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.

Department of Pediatrics, Emory Vaccine Center, Yerkes National Primate Research Center, Emory University School of Medicine, Atlanta, GA 30322, USA.

出版信息

Cell. 2022 Apr 28;185(9):1556-1571.e18. doi: 10.1016/j.cell.2022.03.038. Epub 2022 Mar 25.

DOI:10.1016/j.cell.2022.03.038
PMID:35447072
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8947944/
Abstract

SARS-CoV-2 Omicron is highly transmissible and has substantial resistance to neutralization following immunization with ancestral spike-matched vaccines. It is unclear whether boosting with Omicron-matched vaccines would enhance protection. Here, nonhuman primates that received mRNA-1273 at weeks 0 and 4 were boosted at week 41 with mRNA-1273 or mRNA-Omicron. Neutralizing titers against D614G were 4,760 and 270 reciprocal ID at week 6 (peak) and week 41 (preboost), respectively, and 320 and 110 for Omicron. 2 weeks after the boost, titers against D614G and Omicron increased to 5,360 and 2,980 for mRNA-1273 boost and 2,670 and 1,930 for mRNA-Omicron, respectively. Similar increases against BA.2 were observed. Following either boost, 70%-80% of spike-specific B cells were cross-reactive against WA1 and Omicron. Equivalent control of virus replication in lower airways was observed following Omicron challenge 1 month after either boost. These data show that mRNA-1273 and mRNA-Omicron elicit comparable immunity and protection shortly after the boost.

摘要

SARS-CoV-2 的奥密克戎变体传播性很强，并且对基于原始刺突蛋白匹配疫苗的免疫具有很强的抗性。目前尚不清楚使用奥密克戎匹配疫苗进行加强免疫是否会增强保护效果。在这项研究中，接受了 0 周和 4 周 mRNA-1273 接种的非人类灵长类动物在第 41 周时使用 mRNA-1273 或 mRNA-Omicron 进行了加强免疫。第 6 周（峰值）和第 41 周（预加强）时，针对 D614G 的中和滴度分别为 4760 和 270 倒数 ID，针对奥密克戎的中和滴度分别为 320 和 110。加强免疫后 2 周，针对 D614G 和奥密克戎的滴度分别增加到 mRNA-1273 加强免疫的 5360 和 2980，mRNA-Omicron 的 2670 和 1930。针对 BA.2 的中和滴度也观察到了类似的增加。在接受任何一种加强免疫后，70%-80%的刺突特异性 B 细胞对 WA1 和奥密克戎具有交叉反应性。在加强免疫后 1 个月，奥密克戎挑战后下呼吸道的病毒复制得到了类似的控制。这些数据表明，mRNA-1273 和 mRNA-Omicron 在加强免疫后不久会产生相当的免疫和保护效果。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ceb/8947944/b871e957ebd7/gr6_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ceb/8947944/3f57e3f3c87a/fx1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ceb/8947944/3092a405383c/figs1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ceb/8947944/c7a5e2877b45/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ceb/8947944/c1d294df44b4/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ceb/8947944/7c425eea41d8/figs2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ceb/8947944/6673e860511b/gr3_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ceb/8947944/1046d58b7dce/gr4_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ceb/8947944/039bc640039a/figs3_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ceb/8947944/1333967e2c31/figs4_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ceb/8947944/0481237684d6/figs5_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ceb/8947944/90254aa33c2a/figs6_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ceb/8947944/17b0701f19e3/figs7_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ceb/8947944/46d0c4ea3a48/figs8_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ceb/8947944/8753f4aef60c/figs9_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ceb/8947944/07b2ab411265/figs10_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ceb/8947944/7dde0cbf1f05/gr5_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ceb/8947944/b871e957ebd7/gr6_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ceb/8947944/3f57e3f3c87a/fx1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ceb/8947944/3092a405383c/figs1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ceb/8947944/c7a5e2877b45/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ceb/8947944/c1d294df44b4/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ceb/8947944/7c425eea41d8/figs2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ceb/8947944/6673e860511b/gr3_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ceb/8947944/1046d58b7dce/gr4_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ceb/8947944/039bc640039a/figs3_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ceb/8947944/1333967e2c31/figs4_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ceb/8947944/0481237684d6/figs5_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ceb/8947944/90254aa33c2a/figs6_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ceb/8947944/17b0701f19e3/figs7_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ceb/8947944/46d0c4ea3a48/figs8_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ceb/8947944/8753f4aef60c/figs9_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ceb/8947944/07b2ab411265/figs10_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ceb/8947944/7dde0cbf1f05/gr5_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ceb/8947944/b871e957ebd7/gr6_lrg.jpg

相似文献

1
mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits similar B cell expansion, neutralizing responses, and protection from Omicron.mRNA-1273 或 Omicron 加强针在接种疫苗的猕猴中引发相似的 B 细胞扩增、中和反应，并提供针对 Omicron 的保护。
Cell. 2022 Apr 28;185(9):1556-1571.e18. doi: 10.1016/j.cell.2022.03.038. Epub 2022 Mar 25.
2
Ipsilateral or contralateral boosting of mice with mRNA vaccines confers equivalent immunity and protection against a SARS-CoV-2 Omicron strain.mRNA 疫苗对小鼠进行同侧或对侧增强免疫可提供针对 SARS-CoV-2 奥密克戎株的等效免疫和保护。
J Virol. 2024 Sep 17;98(9):e0057424. doi: 10.1128/jvi.00574-24. Epub 2024 Aug 28.
3
Rapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV-2 Omicron variant.疫苗对 SARS-CoV-2 奥密克戎变异株增强的中和抗体迅速下降。
Cell Rep Med. 2022 Jul 19;3(7):100679. doi: 10.1016/j.xcrm.2022.100679. Epub 2022 Jun 20.
4
Vaccination and Omicron BA.1/BA.2 Convalescence Enhance Systemic but Not Mucosal Immunity against BA.4/5.接种疫苗和奥密克戎 BA.1/BA.2 感染恢复期增强了针对 BA.4/5 的系统性但非黏膜免疫。
Microbiol Spectr. 2023 Jun 15;11(3):e0516322. doi: 10.1128/spectrum.05163-22. Epub 2023 Apr 26.
5
Persistent T cell-mediated immune responses against Omicron variants after the third COVID-19 mRNA vaccine dose.第三剂 COVID-19 mRNA 疫苗接种后针对奥密克戎变异株的持续 T 细胞介导的免疫应答。
Front Immunol. 2023 Jan 23;14:1099246. doi: 10.3389/fimmu.2023.1099246. eCollection 2023.
6
Safety and immunogenicity against ancestral, Delta and Omicron virus variants following a booster dose of an inactivated whole-virus COVID-19 vaccine (VLA2001): Interim analysis of an open-label extension of the randomized, controlled, phase 3 COV-COMPARE trial.在接种一剂灭活全病毒 COVID-19 疫苗（VLA2001）加强针后针对原始株、Delta 株和奥密克戎株变异病毒的安全性和免疫原性：COV-COMPARE 随机对照 3 期试验开放标签扩展的中期分析。
J Infect. 2023 Sep;87(3):242-254. doi: 10.1016/j.jinf.2023.06.022. Epub 2023 Jul 3.
7
Efficacy of mRNA-1273 and Novavax ancestral or BA.1 spike booster vaccines against SARS-CoV-2 BA.5 infection in nonhuman primates.mRNA-1273 和 Novavax 原始或 BA.1 刺突增强疫苗对非人类灵长类动物 SARS-CoV-2 BA.5 感染的疗效。
Sci Immunol. 2023 Oct 27;8(88):eadg7015. doi: 10.1126/sciimmunol.adg7015.
8
Boosting with variant-matched or historical mRNA vaccines protects against Omicron infection in mice.变异匹配或历史 mRNA 疫苗加强接种可预防奥密克戎感染小鼠。
Cell. 2022 Apr 28;185(9):1572-1587.e11. doi: 10.1016/j.cell.2022.03.037. Epub 2022 Mar 28.
9
Surface-modified measles vaccines encoding oligomeric, prefusion-stabilized SARS-CoV-2 spike glycoproteins boost neutralizing antibody responses to Omicron and historical variants, independent of measles seropositivity.表面修饰的麻疹疫苗编码三聚体、预融合稳定的 SARS-CoV-2 刺突糖蛋白，可增强对奥密克戎和历史变异株的中和抗体应答，与麻疹血清阳性无关。
mBio. 2024 Feb 14;15(2):e0292823. doi: 10.1128/mbio.02928-23. Epub 2024 Jan 9.
10
Immunogenicity of mRNA vs. BBV152 vaccine boosters against Omicron subvariants: Final results from Phase B of the PRIBIVAC study, a randomized clinical trial.mRNA 疫苗与 BBV152 疫苗加强针对奥密克戎亚变种的免疫原性：PRIBIVAC 研究 B 阶段的最终结果，一项随机临床试验。
Vaccine. 2024 Nov 14;42(25):126275. doi: 10.1016/j.vaccine.2024.126275. Epub 2024 Sep 5.

引用本文的文献

1
Coordinated early immune response in the lungs is required for effective control of SARS-CoV-2 replication.肺部协调的早期免疫反应是有效控制SARS-CoV-2复制所必需的。
Nat Commun. 2025 Jun 25;16(1):5390. doi: 10.1038/s41467-025-60885-0.
2
Use of a Multiplex Immunoassay Platform to Investigate Multifaceted Antibody Responses in SARS-CoV-2 Vaccinees with and Without Prior Infection.使用多重免疫分析平台研究有或无既往感染的新冠病毒疫苗接种者的多方面抗体反应。
COVID. 2025 Apr;5(4). doi: 10.3390/covid5040044. Epub 2025 Mar 22.
3
Beyond the Pandemic Era: Recent Advances and Efficacy of SARS-CoV-2 Vaccines Against Emerging Variants of Concern.

本文引用的文献

1
Replicating RNA platform enables rapid response to the SARS-CoV-2 Omicron variant and elicits enhanced protection in naïve hamsters compared to ancestral vaccine.复制 RNA 平台使我们能够快速应对 SARS-CoV-2 奥密克戎变异株，与原始疫苗相比，该平台在未经免疫的仓鼠中引发更强的保护作用。
EBioMedicine. 2022 Sep;83:104196. doi: 10.1016/j.ebiom.2022.104196. Epub 2022 Aug 4.
2
Molecular probes of spike ectodomain and its subdomains for SARS-CoV-2 variants, Alpha through Omicron.SARS-CoV-2 变体（阿尔法到奥密克戎）的刺突外域及其亚结构域的分子探针。
PLoS One. 2022 May 24;17(5):e0268767. doi: 10.1371/journal.pone.0268767. eCollection 2022.
3
后疫情时代：SARS-CoV-2疫苗针对新出现的关注变异株的最新进展与效果
Vaccines (Basel). 2025 Apr 17;13(4):424. doi: 10.3390/vaccines13040424.
4
Phenotypic heterogeneity defines B cell responses to repeated SARS-CoV-2 exposures through vaccination and infection.表型异质性通过疫苗接种和感染定义了B细胞对反复暴露于严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的反应。
Cell Rep. 2025 Apr 22;44(4):115557. doi: 10.1016/j.celrep.2025.115557. Epub 2025 Apr 12.
5
Mucosal multivalent NDV-based vaccine provides cross-reactive immune responses against SARS-CoV-2 variants in animal models.基于新城疫病毒的粘膜多价疫苗在动物模型中对SARS-CoV-2变体提供交叉反应性免疫应答。
Front Immunol. 2025 Mar 17;16:1524477. doi: 10.3389/fimmu.2025.1524477. eCollection 2025.
6
A recombinant protein vaccine induces protective immunity against SARS-CoV-2 JN.1 and XBB-lineage subvariants.一种重组蛋白疫苗可诱导针对SARS-CoV-2 JN.1和XBB谱系亚变体的保护性免疫。
Signal Transduct Target Ther. 2025 Feb 26;10(1):58. doi: 10.1038/s41392-025-02154-6.
7
Epitope-focused vaccine immunogens design using tailored horseshoe-shaped scaffold.使用定制的马蹄形支架进行表位聚焦疫苗免疫原设计。
J Nanobiotechnology. 2025 Feb 18;23(1):119. doi: 10.1186/s12951-025-03200-9.
8
Passive infusion of an S2-Stem broadly neutralizing antibody protects against SARS-CoV-2 infection and lower airway inflammation in rhesus macaques.被动输注一种S2茎区广泛中和抗体可保护恒河猴免受SARS-CoV-2感染并减轻下呼吸道炎症。
PLoS Pathog. 2025 Jan 23;21(1):e1012456. doi: 10.1371/journal.ppat.1012456. eCollection 2025 Jan.
9
MHCI trafficking signal-based mRNA vaccines strengthening immune protection against RNA viruses.基于MHC I类分子转运信号的mRNA疫苗增强针对RNA病毒的免疫保护。
Bioeng Transl Med. 2024 Aug 15;10(1):e10709. doi: 10.1002/btm2.10709. eCollection 2025 Jan.
10
Trivalent recombinant protein vaccine induces cross-neutralization against XBB lineage and JN.1 subvariants: preclinical and phase 1 clinical trials.三价重组蛋白疫苗诱导对XBB谱系和JN.1亚变体的交叉中和作用：临床前和1期临床试验
Nat Commun. 2024 Dec 30;15(1):10778. doi: 10.1038/s41467-024-55087-z.
Limited cross-variant immunity from SARS-CoV-2 Omicron without vaccination.
奥密克戎变异株感染诱导的有限交叉免疫，未接种疫苗者尤其如此。
Nature. 2022 Jul;607(7918):351-355. doi: 10.1038/s41586-022-04865-0. Epub 2022 May 18.
4
SARS-CoV-2 Omicron triggers cross-reactive neutralization and Fc effector functions in previously vaccinated, but not unvaccinated, individuals.SARS-CoV-2 奥密克戎在既往接种疫苗而不是未接种疫苗的个体中引发交叉反应性中和及 Fc 效应功能。
Cell Host Microbe. 2022 Jun 8;30(6):880-886.e4. doi: 10.1016/j.chom.2022.03.029. Epub 2022 Mar 25.
5
Outcomes of laboratory-confirmed SARS-CoV-2 infection in the Omicron-driven fourth wave compared with previous waves in the Western Cape Province, South Africa.在南非西开普省，与之前的几波疫情相比，奥密克戎驱动的第四波疫情中实验室确诊的 SARS-CoV-2 感染的结果。
Trop Med Int Health. 2022 Jun;27(6):564-573. doi: 10.1111/tmi.13752. Epub 2022 May 10.
6
mRNA-1273 and BNT162b2 mRNA vaccines have reduced neutralizing activity against the SARS-CoV-2 omicron variant.mRNA-1273 和 BNT162b2 mRNA 疫苗对 SARS-CoV-2 奥密克戎变异株的中和活性降低。
Cell Rep Med. 2022 Jan 24;3(2):100529. doi: 10.1016/j.xcrm.2022.100529. eCollection 2022 Feb 15.
7
The Spread of SARS-CoV-2 Variant Omicron with a Doubling Time of 2.0-3.3 Days Can Be Explained by Immune Evasion.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）变异株奥密克戎以2.0至3.3天的倍增时间传播可由免疫逃逸来解释。
Viruses. 2022 Jan 30;14(2):294. doi: 10.3390/v14020294.
8
Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants.mRNA-1273 对 SARS-CoV-2 奥密克戎和德尔塔变异株的有效性。
Nat Med. 2022 May;28(5):1063-1071. doi: 10.1038/s41591-022-01753-y. Epub 2022 Feb 21.
9
Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity.新冠病毒奥密克戎改变 TMPRSS2 的使用方式影响其感染性和融合性。
Nature. 2022 Mar;603(7902):706-714. doi: 10.1038/s41586-022-04474-x. Epub 2022 Feb 1.
10
SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination.mRNA-1273加强疫苗接种后对SARS-CoV-2奥密克戎变体的中和作用。
N Engl J Med. 2022 Mar 17;386(11):1088-1091. doi: 10.1056/NEJMc2119912. Epub 2022 Jan 26.